title: Do dipeptidyl peptidase-4 inhibitors increase the risk of heart failure?
authors.affiliation: TIMI (Thrombolysis in Myocardial Infarction) Study Group, Brigham and Women's Hospital Heart & Vascular Center, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts. Electronic address: DLBHATTMD@post.harvard.edu.
authors.forename: Deepak L
authors.initials: DL
authors.lastname: Bhatt
authors.affiliation: TIMI (Thrombolysis in Myocardial Infarction) Study Group, Brigham and Women's Hospital Heart & Vascular Center, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts.
authors.forename: Matthew A
authors.initials: MA
authors.lastname: Cavender
mesh_terms: D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D003925:Diabetic Angiopathies / Q000188:drug therapy*; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000627:therapeutic use*; D005260:Female; D006333:Heart Failure / Q000188:drug therapy*; D006801:Humans; D008297:Male; D011719:Pyrazines / Q000627:therapeutic use*; D014230:Triazoles / Q000627:therapeutic use*
chemical_list: D054873:Dipeptidyl-Peptidase IV Inhibitors; D011719:Pyrazines; D014230:Triazoles
keywords: diabetes; heart failure; hospitalization; mortality; sitagliptin